These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 30569597)

  • 1. Efficacy of Long-Term Treatment With Tolvaptan to Prolong the Time Until Dialysis Initiation in Patients With Chronic Kidney Disease and Heart Failure.
    Tanaka A; Hiramatsu E; Watanabe Y; Ito C; Shinjo H; Otsuka Y; Takeda A
    Ther Apher Dial; 2019 Aug; 23(4):319-327. PubMed ID: 30569597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Continuous Administration of Tolvaptan on Preventing Medium-Term Worsening Renal Function and Long-Term Adverse Events in Heart Failure Patients with Chronic Kidney Disease.
    Nakano Y; Mizuno T; Niwa T; Mukai K; Wakabayashi H; Watanabe A; Ando H; Takashima H; Murotani K; Waseda K; Amano T
    Int Heart J; 2018 Jan; 59(1):105-111. PubMed ID: 29332911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Experience with long-term administration of tolvaptan to patients with acute decompensated heart failure.
    Kiuchi S; Fujii T; Hisatake S; Kabuki T; Takashi O; Dobashi S; Ikeda T
    Drug Discov Ther; 2017 Jul; 11(3):133-139. PubMed ID: 28626112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of tolvaptan on advanced chronic kidney disease with heart failure: a randomized controlled trial.
    Komiya S; Katsumata M; Ozawa M; Haze T; Kawano R; Ohki Y; Suzuki S; Kobayashi Y; Fujiwara A; Saka S; Tamura K; Hirawa N
    Clin Exp Nephrol; 2022 Sep; 26(9):851-858. PubMed ID: 35471469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical benefit of tolvaptan in patients with acute decompensated heart failure and chronic kidney disease.
    Uemura Y; Shibata R; Takemoto K; Uchikawa T; Koyasu M; Ishikawa S; Mitsuda T; Miura A; Imai R; Iwamiya S; Ozaki Y; Kato T; Miura T; Watarai M; Murohara T
    Heart Vessels; 2016 Oct; 31(10):1643-9. PubMed ID: 26615607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renoprotection by long-term low-dose tolvaptan in patients with heart failure and hyponatremia.
    Oka T; Hamano T; Ohtani T; Doi Y; Shimada K; Matsumoto A; Yamaguchi S; Hashimoto N; Senda M; Sakaguchi Y; Matsui I; Nakamoto K; Sera F; Hikoso S; Sakata Y; Isaka Y
    ESC Heart Fail; 2021 Dec; 8(6):4904-4914. PubMed ID: 34554640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suitable Dose of Long-Term Tolvaptan to Reduce Heart Failure Rehospitalizations.
    Nishino M; Tanaka A; Kawanami S; Sugae H; Ukita K; Kawamura A; Nakamura H; Matsuhiro Y; Yasumoto K; Tsuda M; Okamoto N; Matsunaga-Lee Y; Yano M; Egami Y; Tanouchi J
    Int Heart J; 2022; 63(1):85-90. PubMed ID: 35095082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical effect of long-term administration of tolvaptan in patients with heart failure and chronic kidney disease.
    Ono Y; Takamatsu H; Inoue M; Mabuchi Y; Ueda T; Suzuki T; Kurabayashi M
    Drug Discov Ther; 2018; 12(3):154-160. PubMed ID: 29998996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early initiation of tolvaptan is associated with early discharge in patients with heart failure regardless of age.
    Kiuchi S; Hisatake S; Kabuki T; Oka T; Dobashi S; Murakami Y; Sano T; Ikeda T
    BMC Cardiovasc Disord; 2022 Apr; 22(1):202. PubMed ID: 35488212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel validated method for predicting the risk of re-hospitalization for worsening heart failure and the effectiveness of the diuretic upgrading therapy with tolvaptan.
    Takimura H; Hada T; Kawano M; Yabe T; Takimura Y; Nishio S; Nakano M; Tsukahara R; Muramatsu T
    PLoS One; 2018; 13(11):e0207481. PubMed ID: 30427915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of add-on tolvaptan in patients with furosemide-resistant congestive heart failure complicated by advanced chronic kidney disease: a sub-analysis of a pharmacokinetics/ pharmacodynamics study.
    Tominaga N; Kida K; Matsumoto N; Akashi YJ; Miyake F; Kimura K; Shibagaki Y
    Clin Nephrol; 2015 Jul; 84(1):29-38. PubMed ID: 25997504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic impact of early treatment with tolvaptan in patients with acute heart failure and renal dysfunction.
    Matsue Y; Suzuki M; Torii S; Yamaguchi S; Fukamizu S; Ono Y; Fujii H; Kitai T; Nishioka T; Sugi K; Onishi Y; Noda M; Kagiyama N; Satoh Y; Yoshida K; Goldsmith SR
    Int J Cardiol; 2016 Oct; 221():188-93. PubMed ID: 27404673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical utility of early use of tolvaptan in very elderly patients with acute decompensated heart failure.
    Niikura H; Iijima R; Anzai H; Kogame N; Fukui R; Takenaka H; Kobayashi N
    Anatol J Cardiol; 2017 Sep; 18(3):206-212. PubMed ID: 28777097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolvaptan's Association with Low Risk of Acute Kidney Injury in Patients with Advanced Chronic Kidney Disease and Acute Decompensated Heart Failure.
    Tagaya T; Hayashi H; Ogata S; Takahashi K; Koide S; Inaguma D; Hasegawa M; Yuzawa Y; Tsuboi N
    Am J Nephrol; 2023; 54(7-8):319-328. PubMed ID: 37385233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the effects of tolvaptan and furosemide on renal water and sodium excretion in patients with heart failure and advanced chronic kidney disease: a subanalysis of the K-STAR study.
    Tominaga N; Kida K; Inomata T; Sato N; Izumi T; Akashi YJ; Shibagaki Y
    Clin Exp Nephrol; 2018 Dec; 22(6):1395-1403. PubMed ID: 29934667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of tolvaptan dose on cardiac mortality in patients with acute decompensated heart failure after hospital discharge.
    Matsumoto K; Ehara S; Nakamura Y; Otsuka K; Kawase Y
    Heart Vessels; 2018 Oct; 33(10):1204-1213. PubMed ID: 29687159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypernatremia induced by low-dose Tolvaptan in a Patient with refractory heart failure: A case report.
    Li T; Li GS
    Medicine (Baltimore); 2019 Jul; 98(27):e16229. PubMed ID: 31277136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemodynamic and Hormonal Effects of Tolvaptan for Heart Failure.
    Kiuchi S; Ikeda T
    Intern Med; 2019 Feb; 58(4):471-475. PubMed ID: 30210135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and safety of Tolvaptan in infants with congenital heart disease.
    Sakaguchi H; Hirano D; Saito A; Takemasa Y; Umeda C; Miwa S; Ito A; Oishi K
    Pediatr Int; 2023; 65(1):e15580. PubMed ID: 37428842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolvaptan Improves Prognosis in Responders with Acute Decompensated Heart Failure by Reducing the Dose of Loop Diuretics.
    Nakamura M; Sunagawa O; Kinugawa K
    Int Heart J; 2018; 59(1):87-93. PubMed ID: 29375117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.